ANNA E BALLENGER
Allopathic & Osteopathic Physicians|Dermatology COLUMBIA, MO NPI 1104566199
Browse related groups: Allopathic & Osteopathic Physicians|Dermatology MO NOVARTIS PHARMACEUTICALS CORPORATION All categories
General Payments — all program years on this page
$701.49
- Category: General Payments
- Program years: PY2024
- Record count: 8
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $701.49 across 8 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $701.49 | 8 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| NOVARTIS PHARMACEUTICALS CORPORATION | $240.35 | 3 |
| Janssen Biotech, Inc. | $123.09 | 1 |
| ABBVIE INC. | $116.23 | 1 |
| GENZYME CORPORATION | $110.22 | 1 |
| UCB, Inc. | $97.07 | 1 |
| PUMA BIOTECHNOLOGY, INC. | $14.53 | 1 |
By program year
| Program year | Amount | Records |
|---|---|---|
| 2024 | $701.49 | 8 |
Records — PY2024 (8)
| Record ID | Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Source |
|---|---|---|---|---|---|---|---|
| 1078782557 | Janssen Biotech, Inc. | $123.09 | 10/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1086741997 | Novartis Pharmaceuticals Corporation | $91.13 | 06/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1086742003 | Novartis Pharmaceuticals Corporation | $80.24 | 09/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1086742005 | Novartis Pharmaceuticals Corporation | $68.98 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1103272333 | ABBVIE INC. | $116.23 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1113841737 | PUMA BIOTECHNOLOGY, INC. | $14.53 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1140004892 | GENZYME CORPORATION | $110.22 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1143493291 | UCB, Inc. | $97.07 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.